natgillin/translations-raw huggingface dataset:
Following administration of the Rapamune oral solution, sirolimus is rapidly absorbed, with a time to peak concentration of 1 hour in healthy subjects receiving single doses and 2 hours in patients with stable renal allografts receiving multiple doses.
Po uporabi peroralne raztopine zdravila Rapamune se sirolimus hitro absorbira in doseže največjo koncentracijo v krvi pri zdravih prostovoljcih po enkratnem odmerku v 1 uri, pri bolnikih s stabilnim presadkom ledvice po večkratnih odmerkih pa po 2 urah.
Following administration of Viekirax, the changes in ombitasvir, paritaprevir, and ritonavir exposures in subjects with mild, moderate and severe renal impairment were similar to those observed when Viekirax was administered with dasabuvir, and are not considered to be clinically significant.
Po uporabi zdravila Viekirax so bile spremembe izpostavljenosti ombitasvirju, paritaprevirju in ritonavirju pri preiskovancih z blago, zmerno in hudo okvaro ledvic podobni, kot če je bilo zdravilo Viekirax uporabljeno z dasabuvirjem, in ne veljajo za klinično pomembne.
Following administration, Ovitrelle may interfere for up to ten days with the immunological determination of serum or urinary hCG, potentially leading to a false positive pregnancy test.
Po dajanju lahko zdravilo Ovitrelle do deset dni vpliva na imunološko določanje serumskega/urinskega hCG, kar lahko povzroči lažno pozitiven nosečnostni test.
Following an 80 mg oral dose of 14C- labeled febuxostat, approximately 49% of the dose was recovered in the urine as unchanged febuxostat (3%), the acyl glucuronide of the active substance (30%), its known oxidative metabolites and their conjugates (13%), and other unknown metabolites (3%).
Po peroralnem odmerku 80 mg s 14C označenega febuksostata se je približno 49 % odmerka izločilo z urinom, 3 % v obliki nespremenjenega febuksostata, 30 % v obliki acil-glukuronida učinkovine, 13 % v obliki znanih oksidativnih presnovkov in njihovih konjugatov ter 3 % v obliki drugih neznanih presnovkov.
Following an additional week the dose may be increased to 450 mg (22.5 ml) per day.
Še 1 teden zatem se lahko odmerek poveča na 450 mg (22,5 ml) na dan.
Following an additional week the dose may be increased to 450 mg per day.
Še 1 teden zatem se lahko odmerek poveča na 450 mg na dan.
Following an additional week the dose may be increased to 450 mg per day.
Še en teden zatem se lahko odmerek poveča na 450 mg na dan.
Following an infusion of Paxene, the patients’ performance at skilled tasks such as driving and operating machines may be impaired due to the alcohol content of Paxene (see section 4.4).
Ker zdravilo Paxene vsebuje alkohol, so lahko po infundiranju pri bolnikih zmanjšane sposobnosti izvajanja določenih spretnosti kot sta vožnja in upravljanje s stroji (glejte poglavje 4.4).
Following an initial dose of ASA, Possia should be used with a maintenance dose of ASA of 75-150 mg (see section 5.1).
Po uvodnem odmerku ASA je treba zdravilo Possia uporabljati z vzdrževalnim odmerkom ASA od 75 do 150 mg (glejte poglavje 5.1).
Following an oral 80-mg dose of 14C-stavudine to healthy subjects, approximately 95% and 3% of the total radioactivity was recovered in urine and faeces, respectively.
Pri zdravih prostovoljcih se je po peroralnem 80-mg odmerku z radioaktivnim izotopom 14C označenega stavudina približno 95% skupne radioaktivnosti izločilo z urinom, 3% pa z blatom.
Following an oral dose of 14C-labelled clopidogrel in man, approximately 50% was excreted in the urine and approximately 46% in the faeces in the 120-hour interval after dosing.
Po peroralnem odmerku s 14C označenega klopidogrela pri človeku se ga je v 120-urnem intervalu po odmerjanju približno 50 % izločilo s sečem in približno 46 % z blatom.
Following an oral dose of 14C-labelled clopidogrel in man, approximately 50% was excreted in the urine and approximately 46% in the faeces in the 120-hour interval after dosing.
Po peroralnem odmerku s 14C označenega klopidogrela pri človeku se ga je v 120-urnem intervalu po odmerjanju približno 50%% izločilo s sečem in približno 46% z blatom.
Following an oral dose of 14C-labelled clopidogrel in man, approximately 50% was excreted in theurine and approximately 46% in the faeces in the 120-hour interval after dosing.
Po peroralnem odmerku s 14C-označenega klopidogrela pri človeku, se ga je približno 50 % izločilo z urinom in približno 46 % z blatom v 120 urnem intervalu po odmerjanju.
Following an oral dose, the apparent terminal elimination half-life is approximately 6.5 h.
Po peroralnem odmerku je bil navidezni končni razpolovni čas izločanja približno 6,5 ure.
Following an oral dose, the apparent terminal elimination half-life is approximately 6.5 h.
Po peroralnem odmerku je bila končna razpolovna doba izločanja približno 6,5 ur.
Following an oral dose, the apparent terminal elimination half-life is approximately 6.5 h.
Po peroralnem odmerku je navidezni končni eliminacijski razpolovni čas približno 6,5 ure.
Following an oral dose, the apparent terminal elimination half-life is approximately 6.5 h.
Po peroralnem odmerku je navidezni končni razpolovni čas izločanja približno 6,5 ur.
Following application of the patch on abdominal skin, maximum serum concentrations of testosterone are reached within 24-36 hours, with a wide inter-individual variability.
Po aplikaciji obliža na kožo trebuha so največje koncentracije testosterona v serumu dosežene v 24–36 urah, z velikimi razlikami med posamezniki.
Following ascending single oral doses (25-675 mg migalastat hydrochloride), no trends were found for clearance, CL/F).
Pri očistku (CL/F) ni bil po dajanju enkratnih naraščajočih peroralnih odmerkov (25–675 mg migalastat hidroklorida) prepoznan noben trend.
Following assessment of this PSUR (reporting period 01 September 2014 –31 August 2015) the PRAC concluded that Acquired Fanconi syndrome (FS) should be included in the section 4.8 of the SmPC with the frequency ‘rare’.
Sledeč oceni navedenega PSUR (obdobje poročanja od 1. septembra 2014 – 31. avgusta 2015) je odbor PRAC zaključil, da je treba pridobljeni Falconijev sindrom vključiti v poglavje 4.8 povzetka glavnih značilnosti zdravila s pogostnostjo »redek«.
Following blood tests, your doctor has decided you need Aranesp as your haemoglobin level is 10 g/dl or less.
Glede na vaše krvne izvide je zdravnik presodil, da potrebujete zdravilo Aranesp, ker imate koncentracijo hemoglobina 100 g/l ali manj.
Following catch-up vaccination in children 12 to 23 months of age, urticaria was reported more frequently (uncommon) compared to the rates observed in infants during primary and booster vaccination.
Po naknadnem cepljenju otrok v starosti od 12 do 23 mesecev so urtikarijo zabeležili pogosteje (občasno) kot pri dojenčkih po primarnem in obnovitvenem cepljenju.
Following chemotherapy, patients should receive radiotherapy.
Predhodna kemoterapija bi morala vključevati antraciklin ali alkilirajočo učinkovino.
Following co-administration of canagliflozin with rifampicin (an inducer of various active transporters and drug-metabolising enzymes), 51% and 28% decreases in canagliflozin systemic exposure (area under the curve, AUC) and peak concentration (Cmax) were observed.
Pri sočasni uporabi kanagliflozina z rifampicinom (ki je induktor številnih aktivnih prenašalcev in encimov, ki presnavljajo učinkovine) so opazili zmanjšanje sistemske izpostavljenosti (AUC- Area Under the Curve) kanagliflozinu za 51% in zmanjšanje najvišje plazemske koncentracije (Cmax) za 28%.
Following co-administration of canagliflozin with rifampicin (an inducer of various active transporters and drug-metabolising enzymes), 51% and 28% decreases in canagliflozin systemic exposure (AUC) and peak concentration (Cmax) were observed.
Pri sočasni uporabi kanagliflozina z rifampicinom (ki je induktor številnih aktivnih prenašalcev in encimov, ki presnavljajo učinkovine) so opazili zmanjšanje sistemske izpostavljenosti (AUC) kanagliflozinu za 51% in zmanjšanje najvišje plazemske koncentracije (Cmax) za 28%.
Following co-administration of oral posaconazole (400 mg twice daily) with atazanavir (300 mg once daily) for 7 days in healthy subjects Cmax and AUC of atazanavir increased by an average of 2.6-fold and 3.7-fold (range 1.2 to 26- fold), respectively.
Pri sočasni uporabi peroralnega posakonazola (v odmerku 400 mg dvakrat na dan) z atazanavirjem (300 mg enkrat na dan) v času 7 dni pri zdravih preiskovancih se je vrednost Cmax za atazanavir povečala v povprečju za 2,6-krat, vrednost AUC pa za 3,7-krat (razpon od 1,2-krat do 26-krat).
Following co-administration, increased incidences of transposed umbilical artery and incomplete ossification of occipital bone were found in rats at doses associated with known glucocorticoid- induced abnormalities.
Po sočasnem dajanju so pri podganah ugotovili pogostejšo pojavnost transpozicije umbilikalne arterije in nepopolno osifikacijo okcipitalne kosti, in sicer pri odmerkih, za katere je znano, da so povezani z nepravilnostmi, ki jih povzročajo kortikosteroidi.
Following coadministration of dapagliflozin with rifampicin (an inducer of various active transporters and drug-metabolising enzymes) a 22% decrease in dapagliflozin systemic exposure (AUC) was observed, but with no clinically meaningful effect on 24-hour urinary glucose excretion.
Po sočasnem jemanju dapagliflozina in rifampicina (induktorja različnih aktivnih prenašalcev in encimov za presnovo zdravil), so zabeležili 22 % zmanjšanje sistemske izpostavljenosti (AUC) dapagliflozinu, vendar brez klinično pomembnega vpliva na 24-urno izločanje glukoze v urinu.
Following coadministration of multiple dose dulaglutide with steady state metformin (immediate release formula [IR]), metformin AUCτ increased up to 15 % and Cmax decreased up to 12 %, respectively, with no changes in tmax.
Ko so aplicirali več odmerkov dulaglutida s sočasno aplikacijo metformina v stanju dinamičnega ravnovesja (zdravilo s takojšnjim sproščanjem [IR – immediate release]), je AUCτ metformina narasla do 15 %, Cmax pa se je zmanjšal do 12 %, brez sprememb v tmax.
Following coadministration of the ABCB1 (P-gp) and ABCG2 (BCRP) inhibitor, elacridar (GF120918) at 100 to 1,000 mg with oral topotecan, the AUC0-∞ of topotecan lactone and total topotecan increased approximately 2.5-fold (see section 4.5 for guidance).
Po sočasni uporabi elakridarja (GF120918) (zaviralca ABCB1 (P-gp) in ABCG2 (BCRP)) v odmerku 100 in 1,000 mg skupaj s peroralnim topotekanom sta se AUC0–∞ topotekanovega laktona in celotnega topotekana povečali približno 2,5-krat (glejte poglavje 4.5 za navodila).
Following coadministration of the ABCB1 (P-gp) and ABCG2 (BCRP) inhibitor, elacridar (GF120918) at 100 to 1,000 mg with oral topotecan, the AUC0-∞ of topotecan lactone and total topotecan increased approximately 2.5-fold (see section 4.5 for guidance).
Po sočasni uporabi elakridarja (GF120918) (zaviralca ABCB1 (P-gp) in ABCG2 (BCRP)) v odmerku 100 in 1.000 mg skupaj s peroralnim topotekanom sta se AUC0–∞ topotekanovega laktona in celotnega topotekana povečali približno 2,5-krat (glejte poglavje 4.5 za navodila).
Following completion of the 52-week active-controlled period, patients were eligible to enter a 4-week placebo-controlled period in which they were re-randomized to receive Fexeric (n=96) or placebo (n=96).
Po koncu 52-tedenskega obdobja z aktivno kontrolo so se lahko bolniki vključili v 4-tedensko, s placebom nadzorovano obdobje, v katerem so bili ponovno naključno razporejeni v skupino, ki je prejemala zdravilo Fexeric (n = 96), ali skupino s placebom (n = 96).
Following completion of the controlled phase of each of the Phase 3 trials, patients who were iron deficient and anaemic could be optionally retreated and receive two additional 510 mg intravenous injections of Rienso for a total cumulative dose of 2.04 g.
Po zaključku kontrolirane faze vsakega od preskušanj 3. faze so imeli bolniki s pomanjkanjem železa in anemijo možnost ponovnega zdravljenja in prejetja dveh dodatnih 510 mg intravenskih injekcij zdravila Rienso do skupnega kumulativnega odmerka 2,04 g.
Following concomitant administration of a single dose bosutinib with six daily doses of 600 mg rifampicin, in 24 healthy subjects in fed state bosutinib exposure (Cmax and AUC in plasma) decreased to 14% and 6%, respectively, of the values when bosutinib 500 mg was administered alone.
Po sočasni uporabi enkratnega odmerka bosutiniba skupaj s šestimi dnevnimi odmerki po 600 mg rifampicina se je izpostavljenost bosutinibu (Cmax in AUC v plazmi) pri 24 zdravih preiskovancih, ki so zdravili vzeli na poln želodec, zmanjšala na 14 % (Cmax) in 6 % (AUC) v primerjavi z vrednostmi, ko je bil 500 mg odmerek bosutiniba uporabljen sam.
Following concomitant administration of a single dose of leflunomide to subjects receiving mult iple doses of rifampicin (non-specific cytochrome P450 inducer) A771726 peak levels were increased by approximately 40 %, whereas the AUC was not significantly changed.
Po sočasni aplikaciji enega samega odmerka leflunomida osebam, ki so prejemale ponavljajoče se odmerke rifampicina (nespecifičnega induktorja citokroma P450), so se najvišje koncentracije A771726 zvišale za približno 40 %, AUC pa se ni pomembno spremenila.
Following concomitant administration of carbamazepine, a potent inducer of CYP3A4, the geometric means of Cmax and AUC for aripiprazole were 68 % and 73 % lower, respectively, compared to when aripiprazole (30 mg) was administered alone.
Po sočasni uporabi karbamazepina, močnega induktorja CYP3A4, je bila geometrična sredina Cmax za 68 % nižja, AUC pa za 73 % nižja kot po uporabi samega aripiprazola (30 mg).
Following concomitant administration of carbamazepine, a potent inducer of CYP3A4, the geometric means of Cmax and AUC for aripiprazole were 68% and 73% lower, respectively, compared to when aripiprazole (30 mg) was administered alone.
Po sočasni uporabi karbamazepina, močnega induktorja CYP3A4, je bila geometrična sredina Cmax za 68 % nižja, AUC pa za 73 % nižja kot po uporabi samega aripiprazola (30 mg).
Following concomitant administration of carbamazepine, a strong inducer of CYP3A4, and oral aripiprazole to patients with schizophrenia or schizoaffective disorder, the geometric means of Cmax and AUC for aripiprazole were 68 % and 73 % lower, respectively, compared to when oral aripiprazole (30 mg) was administered alone.
Po sočasni uporabi karbamazepina, močnega induktorja CYP3A4 in peroralnega aripiprazola pri bolnikih s shizofrenijo ali shizoafektivno motnjo sta bili geometrični sredini Cmax za 68 % in njuni AUC za 73 % nižji kot po uporabi samo peroralnega aripiprazola (30 mg).
Following coronary artery bypass graft surgery, patients administered Dynastat have a higher risk of adverse reactions such as: cardiovascular/ thromboembolic events (including myocardial infarction, stroke/TIA, pulmonary embolus, and deep vein thrombosis; see sections 4.3 and 5.1), deep surgical infections, and sternal wound healing complications.
Po obvodni operaciji koronarnih arterij bolnike, ki dobijo zdravilo Dynastat, bolj ogrožajo neželeni učinki, kot so: kardiovaskularni/tromboembolični dogodki (vključujoč miokardni infarkt, kap/TIA, pljučno embolijo in globoko vensko trombozo; glejte poglavji 4.3 in 5.1), globoke kirurške okužbe in zapleti na sternalni rani.
Following delivery
Po porodu
Following dialysis, a 5 to 10 mg/kg (0.05 to 0.10 ml/kg) supplemental dose is recommended.
Po dializi je priporočljiv dodatni odmerek od 5 to 10 mg/kg (0,05 do 0,10 ml/kg).
Following dilution do not store above 25˚C
Po redčenju shranjujte pri temperaturi do 25 ˚C.
Following dilution in the infusion bag, Doribax infusions stored at room temperature or under refrigeration should be completed according to the times in the following table:
Po redčenju v infuzijski vrečki, je treba infuzije zdravila Doribax, ki so bile hranjene pri sobni temperaturi ali v hladilniku, uporabiti z upoštevanjem časov iz spodnje preglednice:
Following dilution the DARZALEX infusion should be intravenously administered at the appropriate initial infusion rate, as presented in Table 2 below.
Po redčenju zdravila DARZALEX je treba intravensko apliciranje začeti z ustrezno hitrostjo infundiranja, kot je navedeno v preglednici 2.
Following dilution, brivaracetam solution for injection/infusion was found to be physically compatible and chemically stable when mixed with the diluents listed in the section 6.6 for 24 hours and stored in PVC or polyolefin bags at temperature up to 25°C. From a microbiological point of view, the product should be used immediately after dilution.
Ugotovili so, da je raztopina brivaracetama za injiciranje/infundiranje po redčenju fizikalno kompatibilna in kemijsko stabilna 24 ur, če je zmešana s topili, naštetimi v poglavju 6.6, in shranjena v vrečah iz PVC-ja ali poliolefina pri temperaturi do 25 °C. Z mikrobiološkega vidika je treba zdravilo uporabiti takoj po redčenju.
Following dilution, chemical and physical in-use stability in polypropylene infusion bags has been demonstrated for 24 hours when stored below 25 ºC.
Po redčenju se fizikalna in kemijska stabilnost v polipropilenskih infuzijskih vrečah ohrani 24 ur, če so shranjene pri temperaturi do 25 °C.
Following dilution, chemical and physical in-use stability in polypropylene infusion bags has been demonstrated for at least 24 hours below 25 °C. From a microbiological point of view, the diluted product should be used immediately.
Po redčenju se fizikalna in kemijska stabilnot v polipropilenskih infuzijskih vrečah ohrani 24 ur, če so shranjene pri temperaturi do 25 °C. Z mikrobiološkega stališča je razredčeno zdravilo potrebno uporabiti takoj.
Following dilution, chemical and physical in-use stability in polypropylene infusion bags has been demonstrated for at least 24 hours when stored below 25 °C.
Po redčenju se fizikalna in kemijska stabilnot v polipropilenskih infuzijskih vrečah ohrani 24 ur, če so shranjene pri temperaturi do 25 °C.
Following discontinuation of alirocumab, no rebound in LDL-C was observed, and LDL-C levels gradually returned to baseline levels.
Po prenehanju uporabe alirokumaba niso opažali preobratnega učinka ("rebound") na LDL-H; koncentracija LDL-H se je polagoma vrnila na izhodiščno.
Following discontinuation of NovoThirteen the patient’s neutrophil count returned to levels similar to those prior to treatment with NovoThirteen.
Po prenehanju uporabe zdravila NovoThirteen se mu je število nevtrofilcev vrnilo na raven, podobno tisti pred zdravljenjem z zdravilom NovoThirteen.
Following discontinuation of Revolade, platelet counts return to baseline levels within 2 weeks in the majority of patients, which increase the bleeding risk and in some cases may lead to bleeding.
Po prenehanju uporabe zdravila Revolade se število trombocitov pri večini bolnikov vrne na izhodiščno raven v 2 tednih; to poveča tveganje krvavitev in lahko v nekaterih primerih povzroči krvavitve.
Following disease progression, patients were treated at the physician’s discretion with other anti-cancer interventions.
Po napredovanju bolezni so bolnike zdravili po presoji zdravnika z drugimi oblikami zdravljenja raka.
Following doses of 1,200 mg/day, symptoms related to the central nervous system (e.g. dizziness) and the gastrointestinal system (e.g. nausea, vomiting) were observed and resolved with dose adjustments.
Pri odmerkih 1200 mg/dan so opazili simptome, ki so bili povezani z osrednjim živčnim sistemom (npr. omotica) in prebavili (npr. navzea, bruhanje) ter so po ustrezni prilagoditvi odmerka izginili.
Following dulaglutide coadministration, S- and R-warfarin exposure and R-warfarin Cmax were unaffected, and S-warfarin Cmax decreased by 22 %.
Po sočasni aplikaciji dulaglutida ni prišlo do vpliva na izpostavljenost S- in R-varfarina ter na Cmax za R- varfarin, opazili pa so 22% zmanjšanje Cmax S-varfarina.
Following each of two intralesional administrations, separated by 24 hours, of Xiapex 0.58 mg into the penile plaque of 19 patients with Peyronie’s disease, plasma levels of AUX-I and AUX-II in patients with quantifiable levels (82% and 40% for AUX-I and AUX-II, respectively) were minimal and short-lived.
Po dveh intralezijskih aplikacijah 0,58 mg zdravila Xiapex v plak penisa pri 19 bolnikih s Peyroniejevo boleznijo s 24-urnim presledkom, so bile ravni AUX-I in AUX-II v plazmi pri bolnikih z merljivimi ravnmi (82 % za AUX-I in 40 % za AUX-II) minimalne in kratkotrajne.
Following established chemotherapy for solid tumours, lymphomas, and lymphoid leukaemia, it is expected that the duration of treatment required to fulfil these criteria will be up to 14 days.
Pričakovati je, da bo po uveljavljeni kemoterapiji za trdne tumorje, limfome in limfatično levkemijo, zdravljenje, ki je potrebno za izpolnitev teh pogojev, trajalo do 14 dni.
Following first-trimester abortion
Po splavu v prvem trimesečju
Following Grade 3 or 4 diarrhoea, the subsequent dose of ONIVYDE should be reduced, (see section 4.2).
Po driski 3. ali 4. stopnje je treba naslednji odmerek zdravila ONIVYDE zmanjšati (glejte poglavje 4.2).
Following identification of a stable dose of Revolade, perform full blood count (FBC) with white blood cell count (WBC) differential monthly.
Po ugotovitvi stabilnega odmerka zdravila Revolade je treba vsak mesec narediti celotno krvno sliko, vključno z diferencialno belo krvno sliko.
Following implantation, an appropriate regimen of topical and systemic anti-inflammatory and prophylactic antibiotic treatment must be given.
Po implantaciji je treba dajati ustrezen režim topikalnega in sistemskega protivnetnega in profilaktičnega antibiotičnega zdravljenja.
Following improvement to Grade ≤ 2, resume at reduced dose of 400 mg.
Po izboljšanju do stopnje ≤ 2 nadaljujte z zmanjšanim odmerkom 400 mg.
Following improvement to Grade ≤ 2, resume at reduced dose of 400 mg. treatment cycle, the dose may be further increased to 800 mg.
≤ 2 nadaljujte z zmanjšanim odmerkom 400 mg.
Following induction of CYP3A4 by coadministration of rifampicin 600 mg once a day, Cmax and AUC of the active metabolite of fesoterodine decreased by approximately 70% and 75%, respectively, after oral administration of fesoterodine 8 mg.
Po indukciji CYP3A4 s sočasno uporabo rifampicina 600 mg enkrat na dan se je po peroralni uporabi 8 mg fesoterodina vrednost Cmax aktivnega presnovka fesoterodina zmanjšala za približno 70 %, vrednost AUC pa za približno 75 %.
Following influenza vaccination, false positive results in serology tests using the ELISA method to detect antibodies against HIV1, Hepatitis C and especially HTLV1 have been observed.
Po cepljenju proti gripi je prišlo do lažno pozitivnih rezultatov seroloških testov, ki so bili izvedeni po metodi ELISA za odkrivanje protiteles proti HIV1, hepatitisu C in še posebej HTLV1.
Following influenza vaccination, false positive serology test results may be obtained by the ELISA method for antibody to human immunodeficiency virus-1 (HIV-1), hepatitis C virus, and especially, HTLV-1.
Po cepljenju proti gripi je prišlo do lažno pozitivnih rezultatov seroloških testov, ki so bili izvedeni po metodi ELISA za odkrivanje protiteles proti človeškemu virusu imunske pomanjkljivosti 1 (HIV-1), virusu hepatitisa C in še posebej HTLV-1.
Following influenza vaccination, false positive serology test results may be obtained by the ELISA method for antibody to human immunodeficiency virus-1(HIV-1), hepatitis C virus and, especially, HTLV-1 have been observed.
Po cepljenju proti gripi so poročali o lažno pozitivnih rezultatih seroloških testov z metodo ELISA za odkrivanje protiteles proti virusu humane imunske pomanjkljivosti 1 (HIV-1), virusu hepatitisa C in zlasti proti virusu HTLV-1.
Following influenza vaccination, false-positive serology test results may be obtained by the ELISA method for antibody to human immunodeficiency virus-1 (HIV-1), hepatitis C virus and, especially, HTLV-1.
Po cepljenju proti gripi se lahko pojavijo lažno pozitivni serološki testi z metodo ELISA za določanje protiteles proti humanemu virusu imunske pomanjkljivosti (HIV-1), virusu hepatitisa C in zlasti virusi HTLV-1.